ADAMTS4 APP669 Cleavage Assay for Aβ-Modulating Substances
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a clear understanding of the enzyme responsible for cleaving the N-terminal of APP669, which is crucial for controlling the production of Aβ peptides implicated in Alzheimer's disease, necessitating the identification of such an enzyme to develop substances that can regulate its activity.
Innovation Solution
Identification of ADAMTS4 as the enzyme that cleaves the N-terminal of APP669, and development of a screening method involving ADAMTS4 to measure APP669 N-terminal cleavage activity by measuring Aβ-related peptides produced from cultured cells or an in vitro system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to study APP cleavage, then general protease knowledge is available, but specific identification of the enzyme responsible for APP669 N-terminal cleavage is lacking
Solution Approach 1:
The patent uses an intermediary assay system that measures APP669-x peptide levels as a mediator to indirectly identify and quantify ADAMTS4 enzyme activity. This intermediary measurement approach enables precise enzyme identification without requiring direct observation of the cleavage process, resolving the contradiction between measurement precision and system complexity.
Solution Approach 2:
The patent replaces complex direct enzyme characterization methods with a simplified peptide quantification assay. By substituting mechanical/enzymatic analysis with mass spectrometry or immunoassay-based peptide measurement, the system achieves high precision enzyme identification while reducing overall system complexity.
2Reliability
If substances are screened without a specific target enzyme identified, then broad screening is possible, but effective control of APP669 cleavage activity cannot be achieved
Solution Approach 1:
The patent establishes a feedback loop where APP669-x peptide levels are measured and used to evaluate and adjust substance screening results. This feedback mechanism ensures reliable identification of effective substances by continuously monitoring cleavage activity, resolving the contradiction between screening effectiveness and measurement difficulty.
Solution Approach 2:
The patent employs detection methods (such as immunoassays or mass spectrometry) that produce measurable signals proportional to APP669-x peptide concentration. This signal generation approach transforms difficult-to-measure cleavage activity into quantifiable data, enabling effective substance screening with high reliability.
3Object-generated harmful factors
If ADAMTS4 activity is increased to cleave APP669, then Aβ production is suppressed, but excessive cleavage may have unintended effects
Solution Approach 1:
The patent applies partial action by using substances that partially inhibit or activate ADAMTS4 rather than complete inhibition or activation. This partial modulation achieves sufficient Aβ suppression while maintaining enzyme homeostasis and avoiding the harmful effects of excessive cleavage activity, resolving the contradiction between reducing harmful factors and maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the screening of substances that control APP669 N-terminal cleavage activity, potentially leading to the development of preventive or therapeutic agents for Alzheimer's disease by regulating amyloid β production.
Implementation Method 1
A disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4) is one of the enzymes that cleave the N-terminal of APP669
Data Source
AI summary
The present invention provides a method for screening a substance that controls APP669 N-terminal cleavage activity, the method comprising: causing a candidate substance to act on a cultured cell; measuring an Aβ-related peptide produced from the cultured cell; and evaluating APP669 N-terminal cleavage activity. The candidate substance is selected, for example, from the group consisting of a low molecular weight compound, a peptide, a protein, and a nucleic acid. The present invention also provides an APP669 N-terminal cleavage enzyme containing ADAMTS4.